Compare ZWS & IBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ZWS | IBRX |
|---|---|---|
| Founded | 1900 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.4B | 8.2B |
| IPO Year | 2008 | 2015 |
| Metric | ZWS | IBRX |
|---|---|---|
| Price | $45.89 | $8.46 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 7 |
| Target Price | ★ $53.67 | $12.57 |
| AVG Volume (30 Days) | 690.5K | ★ 8.4M |
| Earning Date | 04-21-2026 | 05-08-2026 |
| Dividend Yield | ★ 0.86% | N/A |
| EPS Growth | 25.00 | ★ 38.71 |
| EPS | ★ 0.35 | N/A |
| Revenue | ★ $1,530,500,000.00 | $113,288,000.00 |
| Revenue This Year | $6.90 | $88.59 |
| Revenue Next Year | $5.13 | $131.15 |
| P/E Ratio | $130.66 | ★ N/A |
| Revenue Growth | 19.40 | ★ 668.31 |
| 52 Week Low | $43.06 | $1.95 |
| 52 Week High | $55.00 | $12.43 |
| Indicator | ZWS | IBRX |
|---|---|---|
| Relative Strength Index (RSI) | 36.41 | 57.26 |
| Support Level | $45.86 | $6.68 |
| Resistance Level | $46.24 | $8.51 |
| Average True Range (ATR) | 0.90 | 0.40 |
| MACD | -0.10 | 0.02 |
| Stochastic Oscillator | 18.70 | 68.10 |
Zurn Elkay Water Solutions Corp is a growth-oriented, pure-play water management business that designs, procures, manufactures, and markets the broadest sustainable product portfolio of specification-driven water management solutions to improve health, hydration, human safety and the environment. Its product portfolio includes professional grade water safety and control products, flow systems products, hygienic and environmental products, and filtered drinking water products for public and private spaces that deliver superior value to building owners, positively impact the environment and human hygiene and reduce product installation time.
ImmunityBio Inc is a biotechnology company focused on developing and commercializing next-generation immunotherapies designed to activate the patient's immune system and provide durable protection against cancer and infectious diseases. Its approach harnesses both the adaptive and innate immune systems with the Cancer BioShield platform. The platform is built around the proprietary IL-15 superagonist ANKTIVA (nogapendekin alfa inbakicept) and is supported by a portfolio that includes adenovirus-vectored vaccines, NK-cell therapies, and additional immunomodulators. The company operates in the United States and Europe, with the majority of its revenue coming from the United States.